Bayer AG (FRA:BAYN) received a €125.00 ($147.06) price target from research analysts at Goldman Sachs Group, Inc. (The) in a report issued on Friday. The firm presently has a “buy” rating on the healthcare company’s stock.
Several other research analysts also recently commented on BAYN. UBS Group AG set a €125.00 ($147.06) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Monday, July 3rd. J P Morgan Chase & Co reiterated a “buy” rating on shares of Bayer AG in a report on Thursday. S&P Global set a €126.00 ($148.24) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Thursday. Commerzbank Ag set a €124.00 ($145.88) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Thursday. Finally, equinet AG set a €118.00 ($138.82) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Thursday. Eight investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Bayer AG presently has a consensus rating of “Buy” and a consensus target price of €122.24 ($143.81).
Bayer AG (FRA:BAYN) opened at 112.275 on Friday. Bayer AG has a 1-year low of €85.72 and a 1-year high of €123.83. The firm has a market capitalization of €97.92 billion and a price-to-earnings ratio of 19.421. The stock has a 50 day moving average price of €114.09 and a 200 day moving average price of €112.90.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/bayer-ag-bayn-pt-set-at-125-00-by-goldman-sachs-group-inc-the.html.
Bayer AG Company Profile
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.